|
| Substrate group 1—Metabolic: Overall Effect is anti-diabetic |
|
| GS | Increase glycogen synthesis and glucose disposal (anti-diabetic) |
| Unknown | Turn off hepatic glucose output (anti-diabetic) |
| CREB | Reduce glucagon action (anti-diabetic) |
| IRS1 | Stabilise IRS1 protein and enhance insulin action (anti-diabetic) |
| Inhibitor2 | Inhibit PP1 (not clear if beneficial) |
|
| Substrate group 2—Growth: Predicted effect would be oncogenic, except for effect on mdm2/p53 and PTEN |
|
| BCL3 | Stabilise BCL3 (increased oncogenic potential) |
| c-jun | Induce c-jun activity (increased oncogenic potential) |
| c-myc | Stabilize c-myc protein (increased oncogenic potential) |
| Mcl-1 | Stabilise Mcl-1 (antiapoptotic) |
| p130Rb | Increase p130Rb degradation (cell cycle progression) |
| PTEN | Decrease PI3K signaling (decrease growth factor signaling) |
| IRS1 | Stabilise IRS1 and enhance PI3K signaling (increase growth) |
| HIF1a | Stabilize HIF1a (could induce cell growth) |
| eIF2B | Enhance protein translation (aid cell growth) |
| VDAC | Enhance VDAC interaction with mitochondria (antiapoptotic) |
| CTPS | Enhance CTP production (aid cell growth) |
| FAK | Increase FAK activity (enhance cell spreading and migration) |
| Mdm2 | Stabilise p53 (tumour suppression) |
|
| Substrate group 3—Alzheimer’s disease: Conducive to reducing AD pathology |
|
| Tau | Reduce tangle formation (anti-AD?) |
| APP | Reduce abeta production (anti-AD?) |
| CRMP2 | Regulate axon outgrowth, reduce CRMP2 found in AD (anti-AD?) |
| MARK2 | Reduce tau phosphorylation (anti-AD?) |
| Calcipressin | Regulate calcineurin action (anti-AD?) |
|
| Substrate group 4—Wnt and Hh signaling: Enhanced effect on Wnt and Hh signaling |
|
| b-catenin | Induce b-catenin levels (induce wnt signaling) |
| Axin | Reduce axin levels (induce wnt signaling) |
| APC | Reduce APC b-catenin interaction (induce wnt signaling) |
| Ci155 | Reduce proteolysis of Ci155 (enhanced Hh signaling) |
|
| Substrate group 5—Other possible detrimental effects: |
|
| MAP1B | Reduce MAP1B interaction with microtubules (Wnt7a resistance) |
| MAP2C | Increase MAP2C interaction with microtubules (effect not clear) |
| CLASP2 | Alteration of actin-microtubule interaction (effect not clear) |
| Dynamin I | Reduced presynaptic ADBE (effect not clear) |
| Ngn2 | Impaired motor neuron designation (developmental?) |
| PC2 | Relocalise PC2 (enhance polycystic kidney disease) |
| Myocardin | Enhance mycardin action (cardiac hypertrophy?) |
| NFAT | Nuclear localization (compromise immune system?) |
| Unknown | Suppress IL-1β, IL-6, TNF, IL-12 (compromise immune system?) |
| Unknown | Induction of IL-10 (compromise immune system?) |
|
